Lipocine (NASDAQ:LPCN) Upgraded to “Buy” by StockNews.com

StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN) from a hold rating to a buy rating in a research note issued to investors on Friday.

Lipocine Stock Performance

LPCN stock opened at $4.54 on Friday. The company has a market capitalization of $24.28 million, a P/E ratio of -2.65 and a beta of 1.21. The company has a fifty day moving average price of $4.53 and a 200-day moving average price of $5.56. Lipocine has a 52-week low of $2.31 and a 52-week high of $11.79.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The company had revenue of $0.09 million during the quarter. As a group, sell-side analysts forecast that Lipocine will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.